...
首页> 外文期刊>Gastroenterologie clinique et biologique >Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
【24h】

Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.

机译:靶向TGR5-GLP-1途径来对抗2型糖尿病和非酒精性脂肪肝疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.
机译:基于肠泌素的疗法在2型糖尿病的治疗中已显示出希望。在这里,我们回顾我们目前对TGR5作为诱导胰高血糖素样肽1(GLP-1)分泌的目标的理解。这些新发现表明,TGR5激动剂可能构成治疗2型糖尿病以及糖尿病并发症(如非酒精性脂肪肝)的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号